Telesis Bio approves 1-for-18 reverse stock split to regain Nasdaq bid price compliance

Telesis Bio Inc.

Reverse stock split at 1-for-18 ratio approved by stockholders on May 1, 2024; effective May 9, 2024.
Outstanding shares reduced from ~30.1M to ~1.7M; authorized shares remain at 100M.
Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.
Ticker TBIO unchanged; new CUSIP 192003200; fractional shares rounded up to whole share.

item 3.03 item 5.03 item 5.07 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Telesis Bio Inc.: Effected a 1-for-18 reverse stock split by filing a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-05-09).

Change: charter amendment
Effective: 2024-05-09

Exact text from the filing

the Company filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the Certificate of Amendment) with the Secretary of State of the State of Delaware on May 2, 2024 to effect a reverse stock split of the Company’s Common Stock, par value $0.0001 per share (the Common Stock) at a ratio of 1-for-18 (the Reverse Stock Split).

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Telesis Bio Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split of Common Stock at ratio of 1-for-18 at the 2024-05-01 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2024-05-01

Exact text from the filing

For Against Abstain Broker Non-Votes 31,672,315 321,415 4,710 -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Telesis Bio Inc. shareholders approved Ratify appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-01 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-05-01

Exact text from the filing

For Against Abstain Broker Non-Votes 31,935,240 38,807 24,390 -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Telesis Bio Inc. shareholders approved Election of three Class III directors to serve until the 2027 annual meeting at the 2024-05-01 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-05-01

Exact text from the filing

Nominee Votes For Votes Withheld Percent of Voted Broker Non-Votes Christine A. Tsingo 31,921,084 77,353 99.76% - Jami Nachtsheim 31,847,171 150,037 99.53% 1,229 Annette Tumolo 31,921,201 77,236 99.76% -

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0000950170-24-053596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.